摘要
目的探讨二甲双胍恩格列净、度拉糖肽治疗超重/肥胖型2型糖尿病的临床疗效及安全性。方法方便选取2022年1月—2023年12月聊城市妇幼保健院住院治疗的84例超重/肥胖型2型糖尿病患者为研究对象,按照治疗方法不同分为两组,各42例。对照组用二甲双胍恩格列净片治疗,观察组用度拉糖肽治疗。比较两组临床疗效、血糖水平、体重、腰围、体重指数、不良反应。结果观察组治疗总有效率为95.24%(40/42),高于对照组的80.95%(34/42),差异有统计学意义(χ^(2)=4.087,P=0.043)。治疗后,观察组空腹血糖、餐后2 h血糖、糖化血红蛋白、体重、腰围、体重指数水平均低于对照组,差异有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论度拉糖肽治疗超重/肥胖型2型糖尿病的临床效果显著,可有效降低患者血糖水平、体重及体重指数水平,减小腰围,且不增加不良反应发生率,安全可靠。
Objective To explore the clinical efficacy and safety of metformin empagliflozin and dulaglutide in the treatment of overweight/obese type 2 diabetes.Methods A total of 84 overweight/obese type 2 diabetes mellitus patients hospitalized in Liaocheng Maternal and Child Health Hospital from January 2022 to December 2023 were conveniently selected as the study objects,and they were divided into two groups according to different treatment methods,with 42 cases each.The control group was treated with metformin empagliflozin tablets,and the observation group was treated with dulaglutide.The clinical efficacy,blood glucose levels,body weight,waist circumference,body mass index and adverse reactions were compared between the two groups.Results The total effective rate of treatment of the observation group was 95.24%(40/42),which was higher than 80.95%(34/42)of the control group,and the difference was statistically significant(χ^(2)=4.087,P=0.043).After treatment,the levels of fasting plasma glucose,2-hour postprandial plasma glucose,glycated hemoglobin A1c,body weight,waist circumference and body mass index in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).There was no significant difference in incidence of adverse reactions between the two groups(P>0.05).Conclusion The clinical effect of dulaglutide in the treatment of overweight/obese type 2 diabetes mellitus is significant.Which can effectively reduce the blood glucose levels,body weight and body mass index of patients,reduce waist circumference,and does not increase the incidence of adverse reactions,and it is safe and reliable.
作者
宋琳琳
田晓琴
SONG Linlin;TIAN Xiaoqin(Department of Endocrinology,Liaocheng Maternal and Child Health Hospital,Liaocheng,Shandong,252000,China)
出处
《中外医疗》
2024年第27期110-113,共4页
China & Foreign Medical Treatment
关键词
超重/肥胖型2型糖尿病
二甲双胍恩格列净片
度拉糖肽
临床疗效
Overweight/obesity type 2 diabetes mellitus
Metformin empagliflozin tablets
Dulaglutide
Clinical efficacy